ArticleClinics (Sao Paulo, Brazil)2026
Pharmacokinetic and bioequivalence evaluation of two abiraterone acetate tablets under fasting conditions in healthy Chinese volunteers.
Article in Clinics (Sao Paulo, Brazil), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe combination of abiraterone acetate and prednisone is administered to patients with metastatic castration-resistant prostate cancer who have not responded to docetaxel-based chemotherapy. This study was conducted to assess the bioequivalence between generic and branded 250 mg abiraterone acetate tablets in healthy Chinese participants under fasting conditions.
methodA single-dose, randomized, open-label, three-way, three-period, partially replicated crossover trial design was developed. A total of 45 healthy participants were enrolled and randomly assigned to three groups. Each participant received a single oral dose of either the test formulation (generic abiraterone acetate) or the reference formulation (brand-name abiraterone acetate), followed by a 7-day washout period before receiving the alternate formulation in subsequent periods. Blood samples were collected before dosing and up to 72 h post-dose to determine plasma abiraterone concentrations. These data were used to generate concentration-time curves and to calculate key pharmacokinetic parameters.
resultsOur results indicated that there were no notable differences between the two formulations in terms of peak plasma concentration (C
conclusionsStatistical evaluation confirmed that the generic and branded formulations were bioequivalent when administered under fasting conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.